These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

682 related items for PubMed ID: 21826000

  • 21. Denosumab and the current status of bone-modifying drugs in breast cancer.
    Lee BL, Higgins MJ, Goss PE.
    Acta Oncol; 2012 Feb; 51(2):157-67. PubMed ID: 22150116
    [Abstract] [Full Text] [Related]

  • 22. [Anti-RANKL antibody for treatment of patients with bone metastasis from breast cancer].
    Takahashi S.
    Gan To Kagaku Ryoho; 2012 Jan; 39(1):89-94. PubMed ID: 22241358
    [Abstract] [Full Text] [Related]

  • 23. Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors.
    Lipton A, Balakumaran A.
    Expert Rev Clin Pharmacol; 2012 Jul; 5(4):359-71. PubMed ID: 22943116
    [Abstract] [Full Text] [Related]

  • 24. Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor.
    Rolfo C, Raez LE, Russo A, Reguart N, Campelo RG, Bronte G, Papadimitriou K, Silvestris F.
    Expert Opin Biol Ther; 2014 Jan; 14(1):15-26. PubMed ID: 24161019
    [Abstract] [Full Text] [Related]

  • 25. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A, Scher N, Williams G, Sridhara R, Li N, Chen G, Leighton J, Booth B, Gobburu JV, Rahman A, Hsieh Y, Wood R, Vause D, Pazdur R.
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [Abstract] [Full Text] [Related]

  • 26. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.
    Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, Bosserman LD, Geoghegan C, Hillner BE, Theriault RL, Zuckerman DS, Von Roenn JH, American Society of Clinical Oncology.
    J Clin Oncol; 2011 Mar 20; 29(9):1221-7. PubMed ID: 21343561
    [Abstract] [Full Text] [Related]

  • 27. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
    Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW.
    J Manag Care Pharm; 2011 Oct 20; 17(8):621-43. PubMed ID: 21942303
    [Abstract] [Full Text] [Related]

  • 28. Antiresorptive therapies in oncology and their effects on cancer progression.
    Bundred N.
    Cancer Treat Rev; 2012 Oct 20; 38(6):776-86. PubMed ID: 22370427
    [Abstract] [Full Text] [Related]

  • 29. Safety considerations for use of bone-targeted agents in patients with cancer.
    Mortimer JE, Pal SK.
    Semin Oncol; 2010 Jun 20; 37 Suppl 1():S66-72. PubMed ID: 20682374
    [Abstract] [Full Text] [Related]

  • 30. [Inhibition of RANK ligand to treat bone metastases].
    Body JJ.
    Bull Cancer; 2013 Nov 20; 100(11):1207-13. PubMed ID: 24158618
    [Abstract] [Full Text] [Related]

  • 31. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.
    Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman R, Paterson AH, Peterson MC, Fan M, Kinsey A, Jun S.
    J Clin Oncol; 2007 Oct 01; 25(28):4431-7. PubMed ID: 17785705
    [Abstract] [Full Text] [Related]

  • 32. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis.
    Lipton A, Goessl C.
    Bone; 2011 Jan 01; 48(1):96-9. PubMed ID: 20950721
    [Abstract] [Full Text] [Related]

  • 33. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
    Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C.
    Lancet; 2011 Mar 05; 377(9768):813-22. PubMed ID: 21353695
    [Abstract] [Full Text] [Related]

  • 34. Breast cancer bone metastases: denosumab or zoledronic acid?
    van der Pluijm G.
    Nat Rev Endocrinol; 2011 Mar 05; 7(3):134-5. PubMed ID: 21343953
    [No Abstract] [Full Text] [Related]

  • 35. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
    Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S.
    Eur J Cancer; 2012 Nov 05; 48(16):3082-92. PubMed ID: 22975218
    [Abstract] [Full Text] [Related]

  • 36. [Anti-RANKL antibody for the management of bone metastasis].
    Yoneda T.
    Gan To Kagaku Ryoho; 2011 Sep 05; 38(9):1439-45. PubMed ID: 21918338
    [Abstract] [Full Text] [Related]

  • 37. Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.
    Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.
    Clin Breast Cancer; 2012 Aug 05; 12(4):247-58. PubMed ID: 22694824
    [Abstract] [Full Text] [Related]

  • 38. New approaches to treating and preventing bone metastases.
    Lipton A.
    Curr Opin Support Palliat Care; 2010 Sep 05; 4(3):178-81. PubMed ID: 20703154
    [Abstract] [Full Text] [Related]

  • 39. Effects of bone-targeted agents on cancer progression and mortality.
    Coleman R, Gnant M, Morgan G, Clezardin P.
    J Natl Cancer Inst; 2012 Jul 18; 104(14):1059-67. PubMed ID: 22752060
    [Abstract] [Full Text] [Related]

  • 40. A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
    Gül G, Sendur MA, Aksoy S, Sever AR, Altundag K.
    Curr Med Res Opin; 2016 Jul 18; 32(1):133-45. PubMed ID: 26451465
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.